Tarsus Pharmaceuticals (TARS) Net Equity Issued and Repurchased (2019 - 2025)

Tarsus Pharmaceuticals' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at -$354000.0 for Q2 2025.

• In Q2 2025, Net Equity Issued and Repurchased fell 29.2% year-over-year to -$354000.0; the TTM figure through Mar 2026 stood at -$354000.0 (down 100.97% YoY), while the FY2025 annual figure was $134.8 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased for Q2 2025 stood at -$354000.0, down from $135.1 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $135.1 million in Q1 2025, with the low at -$98.3 million in Q4 2024.
• The 4-year median for Net Equity Issued and Repurchased is -$246000.0 (2022), against an average of $7.9 million.
• The sharpest annual moves came in 2023 and 2024: Net Equity Issued and Repurchased surged 45685.78% in 2023, then slumped 100.04% in 2024.
• Tarsus Pharmaceuticals' Net Equity Issued and Repurchased stood at -$74.4 million in 2022, then dropped by 7.78% to -$80.1 million in 2023, then slipped by 22.65% to -$98.3 million in 2024, then soared by 99.64% to -$354000.0 in 2025.
• Business Quant data shows TARS's Net Equity Issued and Repurchased at -$354000.0 in Q2 2025, $135.1 million in Q1 2025, and -$98.3 million in Q4 2024.